NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is scheduled to present at the Jefferies 2013 Global Healthcare Conference in London on Thursday, November 21, 2013 at 8:40 a.m. WET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentations have concluded. Interested parties may access the webcast from the investors’ calendar of events page on the NPS website at http://www.npsp.com/calendar. About NPS Pharmaceuticals NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (U.S.)/Revestive® (EU) (teduglutide [rDNA origin]) for injection is approved for adult Short Bowel Syndrome (SBS) patients who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism and submitted its marketing application to the U.S. Food and Drug Administration in October 2013. NPS's earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin.